title: Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies.
authors.affiliation: Myeloma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
authors.forename: Sham
authors.initials: S
authors.lastname: Mailankody
authors.affiliation: Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, Oregon, USA Center for Health Care Ethics, Oregon Health & Science University, Portland, Oregon, USA prasad@ohsu.edu.
authors.forename: Vinay
authors.initials: V
authors.lastname: Prasad
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D056687:Off-Label Use
chemical_list: D000970:Antineoplastic Agents